What Are Peptides Used For? Medical and Wellness Applications

Key Takeaways

• FDA-approved uses: As of April 2026, peptide drugs are FDA-approved for type 2 diabetes, weight management, osteoporosis, prostate cancer, endometriosis, heart failure, HIV-associated lipodystrophy, and acute coronary syndromes, among other conditions.
• Strongest evidence: GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) have the largest clinical trial evidence base in the approved peptide category, including multiple Phase 3 trials with tens of thousands of participants.
• Dietary uses: Hydrolyzed collagen peptides and dairy-derived bioactive peptides have been studied in human trials for skin, joint, and cardiovascular outcomes, with variable evidence quality.
• Research peptides: Many compounds marketed for body composition, recovery, and anti-aging are not FDA-approved for any human indication and carry primarily preclinical data. As of April 2026, FDA has foreclosed routine Section 503A compounding of several of these compounds — including BPC-157 and TB-500 — through the Category 2 "significant safety risks" framework and the February 2026 restricted-access reclassification; the April 2026 FDA actions further narrowed available compounding pathways.
• Cosmetic uses: Signal, carrier, and neurotransmitter-inhibitor peptides are regulated as cosmetic ingredients. Physiological effect claims beyond skin appearance are not FDA-supported for this category.

What Peptides Are Used for in Medicine

Peptide therapeutics represent a broad drug category with applications across multiple disease areas. Wang and colleagues, in a comprehensive 2022 review in Signal Transduction and Targeted Therapy, reviewed therapeutic peptide applications, covering production advances, chemical modification strategies, and the expanding pipeline of clinical candidates. Lau and Dunn, writing in Bioorganic and Medicinal Chemistry in 2018, catalogued approved peptide drugs — over 60 FDA-approved in the United States at the time of publication, with the approved class expanding since — spanning metabolic disease, oncology, cardiovascular disease, endocrinology, and infectious disease. The mechanism underlying this diversity is structural specificity: peptides bind defined receptors and trigger specific intracellular cascades, which supports receptor-targeted pharmacology. Fetse and colleagues, in a 2023 review in Trends in Pharmacological Sciences, reviewed peptide chemical modification strategies — cyclization, D-amino acid substitution, N-methylation — that improve stability and extend half-life beyond that of unmodified natural sequences.

Metabolic disease and weight management

The most widely discussed therapeutic application of peptides as of 2026 is metabolic disease, driven by the clinical success of GLP-1 receptor agonists. Liu and colleagues, in a 2018 review in Diabetes, Obesity and Metabolism, reviewed insulin precursor biosynthesis — the peptide that has anchored diabetes therapy for more than a century. GLP-1 receptor agonists have since expanded this category substantially. In the STEP 1 trial, Wilding and colleagues, publishing in the New England Journal of Medicine in 2021 with 1,961 participants, reported the STEP 1 trial results — participants randomized to semaglutide 2.4 mg weekly achieved a mean 14.9% body weight reduction compared to 2.4% with placebo over 68 weeks in adults with obesity or overweight. Popoviciu and colleagues, in a 2023 review in the International Journal of Molecular Sciences, reviewed GLP-1 receptor agonist clinical trial data across multiple approved agents, covering weight loss, blood glucose, blood pressure, and cardiovascular outcomes. Glucagon has a parallel therapeutic use: Quesada and colleagues, reviewing glucagon physiology in the Journal of Endocrinology in 2008, documented glucagon's therapeutic use for emergency hypoglycemia — the earliest FDA-approved glucagon kits remain in clinical use today. Full evidence reviews for semaglutide and tirzepatide cover the trial data in detail.

Endocrine and hormonal conditions

Peptide hormones and their synthetic analogues address a wide range of endocrine conditions. Tesamorelin, an FDA-approved synthetic GHRH analogue, is used for HIV-associated lipodystrophy — a condition involving abnormal fat distribution in patients on antiretroviral therapy. The tesamorelin approval is supported by multiple Phase 3 randomized controlled trials with visceral adipose tissue reduction as the primary endpoint; the tesamorelin page covers the full trial record. GnRH agonists (leuprolide) and antagonists (degarelix) are used in prostate cancer, endometriosis, and uterine fibroids by suppressing gonadal hormone production through pituitary receptor modulation. Ghigo and colleagues, in a 1997 review in the European Journal of Endocrinology, reviewed synthetic GH-releasing peptides in growth hormone deficiency — a category that contributed to the development of the GH secretagogue class.

Cardiovascular conditions

Peptides have several cardiovascular applications, including both therapeutic use and diagnostic biomarker use. Nesiritide — a recombinant form of human B-type natriuretic peptide (BNP) — is FDA-approved for acute decompensated heart failure. Kuwahara, writing in Pharmacology and Therapeutics in 2021, reviewed ANP and BNP clinically, illustrating how the same peptide can be used diagnostically (the BNP blood test) and therapeutically (nesiritide infusion). Boerrigter and colleagues, writing in Expert Opinion on Investigational Drugs in 2004, reviewed exogenous BNP in heart failure as developed from the endogenous natriuretic peptide system. Eptifibatide — a cyclic peptide GP IIb/IIIa inhibitor — is approved for acute coronary syndromes. Potter and colleagues' 2009 review in the Handbook of Experimental Pharmacology reviewed natriuretic peptide cardiovascular physiology.

Oxytocin: obstetrics and investigational applications

Oxytocin, a 9-amino-acid hypothalamic-pituitary peptide, has long-established FDA-approved clinical use in labor induction and postpartum hemorrhage management. Carter, in a 2014 review in the Annual Review of Psychology, reviewed oxytocin in social behavior. Lawson and colleagues, in a 2024 review in Comprehensive Psychoneuroendocrinology, reviewed oxytocin's therapeutic potential in mental health, bone metabolism, and appetite regulation — emerging applications being investigated in clinical trials. None of these non-obstetric applications are currently FDA-approved indications for oxytocin. Yeo and colleagues, writing in Biomedicines in 2022, reviewed neuropeptide therapeutic potential for neurological diseases, citing specificity and blood-brain-barrier penetration not achievable with many small molecules.

Antimicrobial and immune applications

Natural antimicrobial peptides (AMPs) are part of the innate immune defense and have been investigated as drug-development leads for antimicrobial resistance. Ganz, in a 2003 review in Nature Reviews Immunology, reviewed defensins as innate-immune antimicrobial peptides with broad-spectrum activity against bacteria, fungi, parasites, and viruses. Several FDA-approved peptide antibiotics are in clinical use; research pipelines are actively developing novel AMPs as alternatives in the context of growing antibiotic resistance, though most novel AMP candidates remain in early clinical stages as of April 2026.

Peptide Uses in Nutrition and Wellness

Outside pharmaceutical medicine, peptides have established uses in dietary nutrition and emerging uses in functional food development. Evidence quality in these categories is more variable than in the pharmaceutical context.

Collagen peptides and skin health

Hydrolyzed collagen peptides are the most widely consumed peptide supplement category. Barati and colleagues, in a 2020 systematic review in the Journal of Cosmetic Dermatology, reviewed collagen peptides and skin outcomes — finding effects on skin elasticity, hydration, and wrinkle depth outcomes across multiple randomized trials, via proposed effects on fibroblast activity. The comparison of bone broth versus collagen peptides as dietary sources illustrates the practical distinctions in bioavailability and evidence base.

Food-derived bioactive peptides

Dietary proteins release bioactive peptide sequences upon digestion or fermentation that may have modest cardiovascular, antioxidant, or metabolic effects. Chou and colleagues, in a 2012 review in Progress in Molecular Biology and Translational Science, reviewed dietary protein-derived bioactive peptides affecting gene expression and metabolism. Kaur and colleagues, in a 2021 review in Food Chemistry, reviewed food-derived peptides that inhibit ACE — an enzyme involved in blood pressure regulation — as potential nutritional adjuncts for cardiovascular health. Zaky and colleagues, writing in Frontiers in Nutrition in 2022, reviewed food-derived bioactive peptides with antioxidant, anti-inflammatory, anticancer, and antihypertensive applications, and provided a taxonomy of functional food peptide categories. Peighambardoust and colleagues, in a 2021 review in Biomolecules, reviewed food-derived functional peptide ingredients with antihypertensive, antioxidant, and antimicrobial properties. The evidence for specific food-derived peptides producing clinically meaningful blood pressure reduction in human trials is mixed; effects are typically modest at achievable dietary doses.

Peptide Uses in Skincare

Topical cosmetic peptides are a distinct regulatory category from pharmaceutical or dietary peptides. Venkatesan and colleagues, in a 2017 review in Marine Drugs, reviewed marine peptides in cosmetic applications including antioxidant, antimicrobial, anti-aging, and tissue-regeneration formulations. These are classified as cosmetic ingredients by the FDA and are not evaluated for physiological drug effects. Signal peptides (which may stimulate collagen synthesis), carrier peptides (which deliver trace elements to the skin), and neurotransmitter-inhibitor peptides (which may reduce muscle-contraction-related wrinkles) are the three main functional categories used in cosmeceutical formulations. Evidence for topical peptide efficacy in humans is largely from manufacturer-funded clinical studies with small sample sizes and subjective endpoints.

Research and Investigational Uses

A large category of synthetic peptides is under investigation in laboratory and animal models for body composition, tissue repair, and recovery applications. Henninot and colleagues, in a 2018 review in the Journal of Medicinal Chemistry, reviewed peptide therapeutic pipeline interest, providing context for why research activity in this category is high. Sharma and colleagues, writing in Drug Discovery Today in 2023, reviewed peptide drug discovery advances and the clinical pipeline of candidates moving toward approval. As of April 2026, compounds such as BPC-157, TB-500, MOTS-c, and most GH secretagogues are not FDA-approved for any human indication. Tesamorelin (Egrifta) is the only currently FDA-approved GHRH analogue; it is approved specifically for HIV-associated lipodystrophy. Sermorelin's prior FDA approval was withdrawn in 2008, and sermorelin dispensed in the U.S. today is compounded rather than FDA-approved. FDA has foreclosed routine Section 503A compounding of several of these compounds — including BPC-157 and TB-500 — through the Category 2 "significant safety risks" framework; the February 2026 restricted-access reclassification and the April 2026 FDA actions further narrowed available compounding pathways. The evidence base for these compounds in humans consists primarily of small observational data or preclinical animal studies; no completed Phase 3 randomized controlled trials support the marketed uses. People who purchase these compounds through online research-chemical or "peptide supplement" channels (which are not dietary supplements in the DSHEA sense — see the DSHEA definition at 21 U.S.C. § 321(ff)) are operating in an unregulated market without manufacturing oversight.

Biomarkers Relevant to Peptide Applications

The relevant bloodwork markers depend on which peptide application is being explored. Across all categories, establishing a baseline before any intervention makes any subsequent biological change interpretable.

• Fasting insulin and glucose: Core metabolic markers for anyone exploring GLP-1 class peptide medications or peptides with metabolic effects. Baseline insulin and glucose characterize the pre-intervention metabolic state.
• HbA1c: The primary endpoint in most metabolic peptide clinical trials. A pre-intervention HbA1c provides a 90-day average of glucose regulation as baseline context.
• IGF-1: Reflects growth hormone axis activity — the primary downstream marker for growth hormone-releasing peptides and GH secretagogues. Monitoring IGF-1 alongside any GH-related peptide is standard clinical practice.
• Lipid panel (triglycerides, LDL, HDL, total cholesterol): Cholelithiasis risk and lipid effects are monitored during GLP-1 agonist therapy. A pre-treatment triglycerides baseline supports interpretation of any metabolic changes.
• hs-CRP: Systemic inflammation marker relevant for peptides studied in anti-inflammatory contexts. A high-sensitivity CRP baseline provides objective inflammatory context.
• Kidney function (eGFR): Renal clearance affects metabolism and elimination of injectable peptides. Impaired kidney function can alter pharmacokinetics. An eGFR baseline is part of standard pre-treatment assessment for FDA-approved peptide drug protocols.

The guide to biomarkers for metabolic health and weight management covers these markers in the context most relevant to GLP-1 class peptide applications.

When These Questions Deserve Professional Attention

If the question driving peptide research is a specific health condition — type 2 diabetes, obesity, osteoporosis, cardiovascular risk — that condition has established clinical evaluation pathways and FDA-approved therapeutic options. The appropriate starting point is a clinician consultation and metabolic bloodwork, not a research peptide purchase. Chandarana and colleagues, in a 2024 review in Current Drug Research Reviews, reviewed peptide therapeutics across diseases — HIV, cancer, diabetes, and other conditions — noting the receptor-targeted pharmacology of FDA-approved peptide compounds. These properties apply to approved compounds under clinical supervision, not to unregulated products purchased online.

The principle underlying a measured, data-driven approach to these questions is at the center of Superpower's approach to preventive health. In a space where evidence quality spans decades of large randomized controlled trials at one end and small preclinical studies at the other, understanding your own baseline biology is the most reliable starting point for any clinical decision.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a broad category, including both FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile. Superpower Health does not prescribe, sell, or facilitate access to peptide compounds that are not FDA-approved for human use.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Non-approved research peptides, often sold labeled "for research use only," are not regulated for human safety, efficacy, or manufacturing quality. Products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

This content is not a substitute for medical advice, diagnosis, or treatment. If you are considering any peptide-based compound, consult a licensed healthcare provider before proceeding. Individual health conditions, medications, and organ function affect both suitability and response.

For information about FDA-approved peptide medications, visit dailymed.nlm.nih.gov. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.

Disclaimer: This page discusses peptides as a category, including both FDA-approved medications and compounds not approved for human use. Superpower Health does not prescribe, sell, or facilitate access to compounds that are not FDA-approved for any indication in the United States. See individual compound pages for availability and regulatory status of FDA-approved peptide medications. This content is for educational and informational purposes only.